Andere Sprachen Puma Biotechnology, Inc.

Aktien

A1J643

US74587V1070

PBYI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
4,95 ^USD	-2,37 %		+2,48 %	+14,32 %

20.03.	Puma Biotechnology plant Beginn einer Brustkrebs-Kombinationsstudie in der zweiten Jahreshälfte; Aktien steigen	MT
20.03.	Puma Biotechnology, Inc. gibt bekannt, dass die FDA den IND-Antrag für Alisertib bei HER2-negativem, Hormonrezeptor-positivem metastasierendem Brustkrebs genehmigt hat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results	18.04.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)	04.04.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	03.04.
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	20.03.
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20.03.
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20.03.
Puma Biotechnology : Corporate Presentation	06.03.
Puma Biotech: Q4 Earnings Snapshot	29.02.
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	29.02.
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results	29.02.
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	29.02.
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	28.02.
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference	22.02.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	15.02.
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13.02.
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13.02.
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference	11.01.
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	11.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Puma Biotechnology, Inc.

Aktien

A1J643

US74587V1070

PBYI

Andere Sprachen

Filter